In conclusion, CAR-IL-15-pNK cells treated with ENT during ex vivo expansion demonstrated enhanced CAR and IL-15 expression, resulting in superior anti-myeloma activity in vivo. The gene discussed is IL15; the disease is plasma cell myeloma.